Drugs / Adipose tissue derived mesenchymal stem cells
Adipose tissue derived mesenchymal stem cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01809769 | Mar 2013 → Mar 2015 | osteoarthritis, knee | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03321942 | Jan 2017 → Dec 2018 | chronic renal failure syndrome, renal fibrosis | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose tissue derived mesenchymal stem cells | “Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.” NCT03321942 ↗2“Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use” NCT01809769 ↗ “Adipose tissue derived mesenchymal stem cells” NCT01809769 ↗ |
| Known as | AMSCs | “This study aims to investigate the biological characteristics of adipose tissue-derived mesenchymal stem cells(AMSCs) and its effect on oxidative stress, inflammation and...” NCT03321942 ↗ |
| Known as | autologous human adipose-derived mesenchymal stem cells | “autologous human adipose-derived mesenchymal stem cells (haMSCs)” PMID 29417902 ↗ Feb 2018 |
| Known as | haMSCs | “autologous human adipose-derived mesenchymal stem cells (haMSCs)” PMID 29417902 ↗ Feb 2018 |
| Modality | Cell therapy | “autologous human adipose-derived mesenchymal stem cells (haMSCs)” PMID 29417902 ↗ Feb 2018 |
| Route | Other | “administrated for intra-articular use” NCT01809769 ↗ |